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Abstract
Background: It has been proposed that switching from annual to biannual (twice yearly) mass community-directed
treatment with ivermectin (CDTI) might improve the chances of onchocerciasis elimination in some African foci. However,
historically, relatively few communities have received biannual treatments in Africa, and there are no cost data associated
with increasing ivermectin treatment frequency at a large scale. Collecting cost data is essential for conducting economic
evaluations of control programmes. Some countries, such as Ghana, have adopted a biannual treatment strategy in selected
districts. We undertook a study to estimate the costs associated with annual and biannual CDTI in Ghana.
Methodology: The study was conducted in the Brong-Ahafo and Northern regions of Ghana. Data collection was organized
at the national, regional, district, sub-district and community levels, and involved interviewing key personnel and
scrutinizing national records. Data were collected in four districts; one in which treatment is delivered annually, two in which
it is delivered biannually, and one where treatment takes place biannually in some communities and annually in others.
Both financial and economic costs were collected from the health care provider’s perspective.
Principal Findings: The estimated cost of treating annually was US Dollars (USD) 0.45 per person including the value of time
donated by the community drug distributors (which was estimated at USD 0.05 per person per treatment round). The cost
of CDTI was approximately 50–60% higher in those districts where treatment was biannual than in those where it was
annual. Large-scale mass biannual treatment was reported as being well received and considered sustainable.
Conclusions/Significance: This study provides rigorous evidence of the different costs associated with annual and biannual
CDTI in Ghana which can be used to inform an economic evaluation of the debate on the optimal treatment frequency
required to control (or eliminate) onchocerciasis in Africa.
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Introduction
Human onchocerciasis or river blindness is a neglected tropical
disease (NTD) caused by the parasitic filarial nematode Onchocerca
volvulus and transmitted by the bites of Simulium blackflies [1]. In
addition to ocular pathology (vision loss, blindness), and increased
host mortality [2,3], onchocerciasis also causes disfiguring skin
lesions and severe dermal itching that can drastically impair an
individual’s quality of life [4]. In 1987, ivermectin was registered
for human use against onchocerciasis, and Merck & Co., Inc.
took the unprecedented decision to donate ivermectin for as long
as needed to eliminate onchocerciasis as a public health problem
[5].
Two major onchocerciasis control programmes have been
launched in Africa. The former was the Onchocerciasis Control
Programme in West Africa (OCP), which started in 1974 and
closed in 2002, and was initially based solely on vector control
until ivermectin was licensed for human use in 1987. For the most
part, the OCP used an annual treatment strategy (alone or in
combination with antivectorial measures), but in the Western
extension, some foci were treated biannually in the absence of
vector control [6,7]. Currently, the former OCP countries
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undertake their own national onchocerciasis control programmes.
The African Programme for Onchocerciasis control (APOC) was
launched in 1995 and it has recently been extended to 2025 [8]. It
targets the 19 onchocerciasis endemic countries in Africa that were
not covered by the OCP (though three of them, Kenya, Rwanda,
and Mozambique, were found not to be endemic) [9]. APOC’s
predominant strategy involves annual, community-directed treat-
ment with ivermectin (CDTI) in areas where the prevalence of
onchocercal nodules is greater than 20%, for all those aged five
years and older (excluding pregnant or breastfeeding women in the
first week after delivery) [9,10].
Based on the experience in Uganda [11], and the success
achieved in most onchocerciasis foci in the Americas [12], there
have been recent discussions of switching to biannual treatments
(twice yearly) to increase the feasibility of elimination. In the past,
only a small number of foci within the OCP (such as River
Gambia in Senegal [7]) have received biannual treatment in
Africa, and therefore there are no ground-truth data on the cost
associated with increasing the treatment frequency to twice per
year on a large scale. (In Uganda, the cost of biannual CDTI was
simply estimated by doubling that of the annual treatment [11].)
Motivated by ivermectin efficacy studies suggesting sub-optimal
responses of O. volvulus to the drug [13,14,15], Ghana (an ex-OCP
country), has recently adopted a biannual treatment strategy at a
large scale [15].
In Ghana, onchocerciasis is endemic in 9 out of 10 regions with
a total at-risk population of approximately 3.2 million [16].
Responsibility for ivermectin distribution—which occurs in 73
districts—was devolved from the OCP to Ghana in 2002 (under
the supervision of APOC). Since 2006, onchocerciasis control has
been implemented in the context of the Neglected Tropical
Diseases Programme (NTDP) [16], and in 2009, 40 (55%) districts
started using a biannual ivermectin distribution strategy. The
decision regarding which areas should change to the biannual
treatment strategy was based on the combined results of rapid
epidemiological mapping of onchocerciasis (REMO) conducted in
Ghana in 2009, parasitological evaluation via skin snipping and
determination of microfilarial prevalence, and entomological
evaluations (according to unpublished results of the Ghana
onchocerciasis mapping exercise conducted in 2009, and the
REMO report summarised in 2010). Areas with an infection
prevalence in the adults above 20%, were allocated to a biannual
treatment frequency considering also a buffer zone of 20 Km
around these CDTI priority areas. Therefore, NTDP decisions as
to whether to allocate districts to annual or biannual CDTI were
not made on a priori criteria of associated costs but only based on
transmission criteria.
In this paper, we report the results of a study undertaken to
estimate the costs associated with annual (the standard strategy) vs.
biannual CDTI (the newly adopted strategy) in Ghana. We also
assess some factors that may hamper the scaling up of treatment
frequency at a large scale given that other countries in the region
may consider switching from annual to biannual ivermectin
distribution.
Methods
Ethics Statement
Ethical approval for the study in Ghana was obtained from
Imperial College Research Ethics Committee (ICREC) and the
Ethics Review Committee (ERC) of the Ghana Health Service
(GHS).
Description of Study Areas
The study focused on the Brong-Ahafo and Northern regions in
Ghana. In the former, data were collected in the Wenchi district
where CDTI takes place annually; the Pru district and the
Figure 1. Map of Ghana indicating the sampled regions and
districts. The Brong-Ahafo and Northern regions are highlighted in
light blue and light pink respectively. 1-Wenchi, 2-Kintampo North, 3-
Pru, 4- Kpandai. Figure prepared by Mr Simon O’Hanlon (Imperial
College London).
doi:10.1371/journal.pntd.0002452.g001
Author Summary
The African Programme for Onchocerciasis Control (APOC)
has recently been extended until 2025, with renewed
commitment towards onchocerciasis elimination. This aim
is aligned with the goals stated by the World Health
Organization and the London Declaration on Neglected
Tropical Diseases in January 2012. Switching from annual
to biannual (twice yearly) ivermectin distribution might
increase the feasibility of onchocerciasis elimination in
some African foci. However, relatively few communities
have received biannual treatments in Africa, and there are
no cost data associated with increasing ivermectin
treatment frequency at a large scale, essential pre-
requisites to provide reliable information for evidence-
based decision making regarding adoption of a biannual
treatment strategy. Therefore, we undertook a study to
estimate costs associated with biannual compared to
annual ivermectin delivery in Ghana, which since 2009 has
implemented a biannual treatment strategy in selected
priority areas. Our results indicate that the cost of biannual
ivermectin treatment per year is approximately 60% higher
than the cost of annual treatment. This study provides
tangible evidence of the different costs associated with
annual and biannual ivermectin treatment, which can be
used to inform economic evaluations and policy decisions
regarding the optimal treatment frequency required to
eliminate onchocerciasis in Africa.
Cost of Annual vs. Biannual CDTI in Ghana
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Kintampo North district, where CDTI is taking place biannually,
and in the latter, data were also collected in the Kpandai district,
where a mixed strategy (some communities being treated annually
and others biannually) is used (Table 1). These districts were
selected partly based on logistics at the time of the study, and
partly because already established relationships with the GHS at
the district and sub-district levels would ensure collection of
accurate data via the purposely designed questionnaires (see
below). Figure 1 shows the locations of the districts where the study
was conducted. As stated earlier, decisions to switch to a biannual
treatment frequency were based on infection and transmission
criteria alone, so there were no obvious reasons why the decision
to change treatment frequency would have been influenced by the
local district-specific programme cost.
Data were collected at various levels in the organization of the
GHS. Firstly, information was gathered by conducting semi-
structured interviews at the headquarters of the NTDP in Accra,
and at the Regional Health Service directorates in the Brong-
Ahafo region. Secondly, districts (and sub-districts where appro-
priate) were chosen to represent a range of geographical sizes, and
population densities (Table 1). Thirdly, community drug distrib-
utors (CDDs) were interviewed in at least three communities in
each district.
Perspective
In this study, the costs under investigation were those borne by
the health care providers (such as the GHS, the major in-country
partners, and the local communities). Therefore the cost of drug
manufacture and transport to Ghana were excluded. Only data on
the cost of CDTI were collected; costs associated with individual,
clinic-based treatment with ivermectin were ignored.
Data were collected on both the financial and economic costs of
CDTI. Financial costs are those where a monetary transaction has
taken place for the purchase of a resource. Economic costs also
include, in addition to the financial costs described above,
estimates of the monetary value of goods or services for which
no financial transaction has taken place. Therefore, economic
costs also account for the value of goods or services which could
have been used for another purpose (opportunity costs). Examples
of resources which have no financial costs but do have important
economic costs are the ‘free’ use of building space provided by the
Ghana Ministry of Health, the use of donated vehicles, and the
time devoted to CDTI by unpaid CDDs. The costs associated with
CDTI arise from various programmatic activities as outlined in
Box 1.
Data Collection
Data collection was organized at the national, regional, district,
sub-district and community levels and involved interviewing key
personnel and scrutinizing national records. Data collected at the
national level included records of funds provided by non-
governmental organizations (NGO) such as Sightsavers (http://
www.sightsavers.org/), and others such as APOC (managed by the
World Bank and implemented by the World Health Organization)
(http://www.who.int/apoc/en/), among others. Given these
multiple sources, it would have been most interesting to obtain a
detailed breakdown of the relative contribution of each organiza-
tion to the funding of onchocerciasis control in Ghana.
Unfortunately, even at the national sampling level, it was rarely
possible to separate the costs by their funding source. This,
however, did not affect the study, which focused on the aggregate
cost of onchocerciasis control. The costs collected were incurred in
the year 2011. At each level, costs were collected according to
different resource types (Box 2) using an approach based on
methods described by McFarland et al. [17] and the UNAIDS
guidelines for costing studies [18]. First, the total gross expenditure
on a resource (per year) was calculated from national records and/
Table 1. Description of ivermectin treatment in the areas where cost data were obtained in Ghana.
Region District Treatment Frequency
Number of
Persons
Treated Per
Year
Overall
Therapeutic
Coverage (%)a Size (km2)
Brong-Ahafo Wenchi Annual in all communities 27,881 90.43 3,494
Brong-Ahafo Kintampo North Biannual in all communities 57,802 82.10 5,108
Brong-Ahafo Pru Biannual in all communities 68,506 88.08 2,195
Northern Kpandai Annual in 122 (55%) and biannual
in 100 (45%) of 222 communitiesb
90,183 79.10 1,772
aFor the Wenchi and Kpandai districts, therapeutic coverage estimates were taken directly from national records pertaining to the last treatment round of 2010. For the
Pru and Kintampo North districts, coverage estimates were derived from an average of two treatment rounds (the last round of 2010 and the first round of 2011).
bA biannual strategy is used in 15 of 76 (20%) communities in the sampled sub-district, whereas the remainder 80% receive treatment annually. Therefore, the costs are
likely to reflect more closely those of annual rather than biannual distribution.
doi:10.1371/journal.pntd.0002452.t001
Box 1. Programmatic Activities (partly based
on [17])
N Drug Distribution Chain: the process of getting the
drugs from where they entered the country to the target
population
N Mobilization and Sensitization: promotion, informa-
tion dissemination and advocacy related to the project
N Training of Volunteers: training of community drug
distributors (CDDs) (includes the costs incurred by both
the trainers and the trainees)
N Other Training: all other training at whatever level
(includes the costs incurred by both trainers and
trainees)
N Reporting: the preparation and transmission of reports
N Surveillance and Evaluation: surveillance of the
disease and treatment distribution at all levels
N All Other Administration: all other general office
administration
N Other Project Activities: all other activities not
already mentioned above
Cost of Annual vs. Biannual CDTI in Ghana
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or questionnaires. Second, the most appropriate person(s) to
answer questions on how the resource is used for activities relating
to onchocerciasis control was selected for interview. Third, the
interviewee was asked to indicate what fraction of time the
resource was used for onchocerciasis control over the year (this was
corroborated by multiple sources where possible). Multiplication of
the total gross cost and fraction of time attributable to
onchocerciasis control yielded an estimate of the recurrent yearly
cost for a resource (such as an employee). The cost of capital
resources—goods that last for more than one year, such as cars
and computers—were estimated in a similar fashion, but the gross
cost was spread over the average useful lifetime of the resource (a
technique known as ‘annualization’) to arrive at an average yearly
cost [18]. (An annualization and discount rate of 3% was used to
calculate the economic costs of capital resources [19].) The
average useful lifetime of all capital goods was assumed to be five
years, in line with the value estimated by McFarland et al. [17] and
corroborated by study participants at the national level. However,
the sensitivity of the results to this assumption was investigated by
varying the average useful lifetime between 5 and 8 years [20].
The annual cost of building space was estimated as the equivalent
market rental value for the space being used for the control
programme [18].
The interviewee was also asked to estimate the fraction of time
that the resource was used for itemized onchocerciasis control
programmatic activities (Box 1). In addition, in districts receiving
ivermectin biannually, the interviewees were asked to describe
how their time spent on different CDTI activities had changed
since increasing the treatment frequency to twice per year, and to
indicate which of the CDTI activities are repeated for both
treatment rounds.
At each level, and where relevant, interviewees were given the
opportunity to express whether they had encountered any specific
difficulties with the increasing of treatment frequency.
Data Analysis
Costs collected at the national and regional levels, were factored
down and costs from the sub-district and community levels
factored up, with the aim of arriving at a value for the cost per
person treated per year in each district (Figure 2). This is described
for each of the levels below.
National costs. Of the 73 districts in Ghana where
ivermectin is distributed, 40 (55%) are implementing biannual
treatment. Consequently, when allocating the national costs to the
districts, the costs were weighted according to the district’s
frequency of treatment. Based on responses to questionnaires,
scrutinizing of national records, and conduction of semi-structured
interviews, it was estimated that districts treating biannually were
responsible for 70% of the total national cost. Separate costs
(according to annual or biannual treatment) were allocated equally
across districts receiving a certain treatment frequency. Based on
interviews at the headquarters of the NTDP and the McFarland et
al. study [17], it was assumed that the main drivers of the national
costs were independent of target population size and therefore we
did not adjust the national costs by the size of districts’ target
populations.
Regional costs. These were distributed among districts using
the same frequency of treatment-based weighting as used for the
national costs. Due to logistic reasons on the terrain, it was only
possible to estimate regional costs from one of the two regions
from which districts were sampled. Thus, the costs incurred by the
Northern region were assumed to be the same as those estimated
from data pertaining to the Brong-Ahafo region.
Sub-district costs. In each district included in this study one
sub-district was sampled. The costs incurred by the sampled sub-
districts were multiplied by the number of sub-districts within each
district to aggregate the costs to the district level.
Community costs. In each district included in this study
three communities were sampled. In each sampled community,
questionnaires were administered to the CDDs to ascertain to how
many people they distributed ivermectin, and whether they
received compensation from the district (this was corroborated at
the local district health centres). Additionally, the opportunity cost
of the volunteer CDDs’ donated time was estimated by asking
CDDs how much time they spent distributing the drug each
treatment round. This donated time was converted to an
Box 2. Resource Types (partly based on [17])
N Transportation (Capital Costs): the capital costs
associated with vehicles (e.g. the annualizeda cost of
motorbikes and cars)
N Transportation (Recurrent Costs): the recurrent
costs associated with transport (e.g. fuel, insurance,
maintenance, repairs, and rental costs)
N Personnel: the recurrent costs associated with paying
salaries to employees (including any supplements or
other benefits of employment)
N Per Diems: the recurrent costs associated with daily
allowances (per diems)
N Supplies and Equipment (Capital Costs): other
capital costs associated with a project, (e.g. annualizeda
costs of computers, photocopiers, and generators etc.)
N Supplies and Equipment (Recurrent Costs): the
recurrent costs associated with project activities and
general office running
N Overheads: the recurrent indirect costs associated with
a project’s specific utilities charges, building rental or
equivalent
N Volunteer Community Drug Distributor (CDD)
Time: the monetary value of the donated time of CDDs
and other community members in implementing com-
munity directed treatment with ivermectin (CDTI)
a The annual share of the initial cost of capital equipment
Figure 2. Organization levels at which data on cost of
ivermectin distribution were collected.
doi:10.1371/journal.pntd.0002452.g002
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equivalent number of 8-hour working days, which were valued
according to the minimum wage in Ghana in 2011 (3.73 Ghana
Cedis (GHC) per day [21]). This figure was reported to be
equivalent to the daily wage of a hired farmland worker in the
Brong-Ahafo region, the occupation of the majority of the
interviewed distributors, and was subsequently used to estimate
the value of the CDDs donated time across each district. However,
to place a precise value on a CDD’s donated time is difficult and
whether or not it should be included is a matter of debate.
Furthermore, the daily wage of a hired farmland worker can vary
from district to district, and especially from region to region
[20,22]. Therefore, we calculated the economic cost both
including and excluding CDD’s donated time, and investigated
the sensitivity of the results to the assumed daily wage (increasing
or decreasing it by GHC 1.00).
Currency conversion. All costs were converted from the
Ghanaian local currency (GHC), to United States dollars (USD),
using the average 2011 exchange rate of USD 1.00 to GHC 1.58
[23]. Reported costs from other studies were also converted to
2011 US dollars (using a consumer price index inflation calculator
[24]) to allow for valid comparison with our results.
Results
Table 2 shows the estimated financial and economic costs—
including and excluding volunteer CDDs’ time—of CDTI in the
four sampled districts. The majority of the costs associated with
CDTI were financial, with the extra economic cost per person per
year (excluding CDDs’ time) only adding USD 0.01–USD 0.03
(this includes the value of donated vehicles and use of free building
space).
The estimated economic cost (excluding CDDs’ time) of annual
treatment in Wenchi district is USD 0.40 per person per year. The
economic costs (excluding CDD’s time) of biannual treatment in
the Pru and Kintampo North districts are approximately 50–60%
higher (USD 0.60 and USD 0.64 per person per year respectively)
than the corresponding annual costs. The estimated economic cost
(excluding CDDs’ time) for Kpandai district—which uses a
combination of an annual and biannual strategy (see Table 1 for
description)—is USD 0.43 per person per year. These results were
not sensitive to the assumed average useful lifetime of capital
goods; changing this from 5 to 8 years only changed the cost per
treatment by a maximum of USD 0.015.
Costs Disaggregated by Resource Type and
Programmatic Activity
Figure 3 depicts the cost of onchocerciasis control by CDTI
disaggregated by resource type in the four sampled districts. The
largest proportion of the total cost was associated with the
payment of personnel. Recurrent transportation costs, such as the
costs of fuel and vehicle maintenance, were the next most costly
resource and showed the most variation among districts.
Figure 4 depicts the cost of CDTI-based onchocerciasis control
disaggregated by programmatic activity in the four sampled
districts. Surveillance and evaluation incurred the highest cost,
followed by the drug distribution chain. For Pru and Kintampo
North districts, the data show a noticeable increase in the
reporting cost compared to Wenchi district.
Community Distributors
From the pooled community data, it was estimated that there is
one CDD for every 390 people and they spend an average of
61 hours distributing ivermectin each treatment round. The above
value was used with data on the number treated in each district
(Table 1) to estimate the total amount of time CDDs spend
distributing the drug across the whole district. This increased the
economic cost by USD 0.046 per person per year when treating
annually, and by USD 0.092 when treating biannually (Table 2).
This result was robust to the assumed daily wage of a hired
farmland worker, which when increased or decreased by GHC
1.00, only changed the economic cost of CDD per treatment by
plus or minus USD 0.012.
The CDDs reported receiving an average equivalent of USD
3.17 in compensation for attending the distribution training
sessions (which are conducted before each treatment round), and
between USD 3.17 and USD 9.52 after distributing the drug. In
this analysis, it was assumed that each distributor received the
average (arithmetic mean) of the reported values (a total of USD
9.96 in compensation for both training and distribution for each
treatment round).
Reported Difficulties
The implementation of a large-scale, mass biannual ivermectin
treatment strategy was reported at the district and sub-district level
as being well received and perceived as sustainable in the future.
However, the disease control officers at the district health centres
in the sampled districts in which biannual treatment is being
implemented, reported that increasing the treatment frequency to
twice per year substantially increased the workload by increasing
Table 2. Financial and economic costs (USDa) per person treated per year in each district.
Frequency of CDTIb Annual Biannual Biannual Mixedc
Cost type Wenchi Kintampo North Pru Kpandai
Financial cost 0.39 0.62 0.58 0.40
Economic cost (excluding volunteer CDD’sd time) 0.40 0.64 0.60 0.43
Economic coste (including volunteer CDD’s time) 0.45 0.73 0.69 0.50
aUSD: US Dollars.
bCDTI: Community-directed treatment with ivermectin.
cData from Kpandai district reflect a combination of annual (in 61 of 76 (80%) of the communities in the sampled sub-district) and biannual treatment frequency (see
Table 1 and main text).
dCDD: Community Drug Distributor.
eEconomic costs include financial costs (monetary transactions) and estimates of the monetary value of goods or services for which no financial transaction has taken
place (for example, the opportunity cost of the CDDs’ time donated to administer ivermectin rather than working their fields) [18].
doi:10.1371/journal.pntd.0002452.t002
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the amount of time they spent on reporting activities (the
percentage of the economic cost at the district, sub-district, and
community levels attributed to reporting activities increased from
6% in the districts (Wenchi) treated annually to 15% in the
districts treated biannually (Pru and Kintampo North) (Figure 4)).
Discussion
The estimated economic cost of annual CDTI in Wenchi
district, i.e. USD 0.40 per person per year excluding CDDs’ time,
is consistent with the lower range of costs reported by McFarland
et al. [17], who estimated an average economic cost (excluding
CDDs’ time) of USD 0.62 (2011 prices) per person per year from
10 regions (excluding one region co-endemic with Loa loa) across
Cameroon, Nigeria and Uganda (with values ranging from USD
0.39 to USD 2.77 (2011 prices)). The estimated cost of annual
CDTI presented here is 1.4 times higher than the USD 0.29 (2011
prices) per person estimated by Onwujekwe et al. [25] using data
from two Nigerian communities. However, the Nigerian study
used a smaller sample of only two communities, and did not collect
costs from as an extensive range of sources as we did here, or as
done by McFarland et al. [17]. Katabarwa et al. [26] estimated that
in districts of a similar population size to Wenchi, the cost per
treatment was USD 0.34 (2011 prices) [26]. However, in districts
with a larger population (.100,000 inhabitants) the cost fell
substantially to USD 0.13 (2011 prices) [26]. These estimates are
Figure 3. Economic costs at district, sub-district, and community levels disaggregated by resource type (excluding CDDs’ time).
Personnel (dark blue); Per Diems (red); Supplies and Equipment (Capital costs) (green); Supplies and Equipment (Recurrent costs) (purple); Transportation
(Capital costs) (turquoise blue); Transportation (Recurrent costs) (orange); Overheads (light blue). Definitions of different resource types are given in Box
2. *Data from Kpandai district reflect a combination of annual and biannual treatments.
doi:10.1371/journal.pntd.0002452.g003
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broadly consistent with the cost of annual mass drug administra-
tion (MDA) for lymphatic filariasis control presented by Goldman
et al. [27], in which the estimated financial cost per treatment (with
donated ivermectin and albendazole) in Ghana was USD 0.21
(2011 prices) but varied between USD 0.08 and USD 2.91 (2011
prices) across the whole multi-country study.
The estimated cost of biannual CDTI per person per year in the
Pru and Kintampo North districts was 50–60% higher than the
estimated cost of annual (in Wenchi) treatment. This is consistent
with the estimated increase in costs associated with biannual MDA
for lymphatic filariasis control provided by Stolk et al. [28] (who
estimated for Africa, a 63% increase in the cost of treatment per
year excluding the value of donated drugs). These costs are higher
than estimates for biannual treatment at smaller scales and specific
age groups, such as in school-based anthelmintic treatment
programmes. For instance, Phommasack et al. [29] found that
the annual cost of treatment of soil-transmitted helminthiases in a
school-based programme was 35% higher in provinces treating
biannually than in those treating annually. However, school-based
treatment programmes are implemented differently than commu-
nity-based programmes and therefore the change in costs of
different treatment frequencies cannot be directly compared.
Figure 4. Economic costs at district, sub-district, and community levels disaggregated by programmatic activity (excluding CDDs’
time). Training of Volunteers (dark blue); All Other Training (red); Mobilization/Sensitization (green); Drug Distribution Chain (purple); Surveillance and
Evaluation turquoise blue); Reporting (orange); All Other Administration (light blue); Other Project Activities (pink). Definitions of programmatic activities
are given in Box 1. *Data from Kpandai district reflect a combination of annual and biannual treatments.
doi:10.1371/journal.pntd.0002452.g004
Cost of Annual vs. Biannual CDTI in Ghana
PLOS Neglected Tropical Diseases | www.plosntds.org 7 September 2013 | Volume 7 | Issue 9 | e2452
Caution is also advised when comparing the costs of different
strategies estimated using data from different districts. This is
because districts have different characteristics, such as road
conditions, spread of communities, and population densities,
which will affect the estimated cost of CDTI. Because of these
potential difficulties, study participants in the Pru and Kintampo
North districts were asked to estimate—based on their previous
experience—the percentage allocated to a given resource had this
resource hypothetically been used for an annual treatment
strategy. Thus, the estimated hypothetical economic cost
(Table 3) of treating annually in the Pru and Kintampo North
districts (USD 0.39 and USD 0.43 per person per year,
respectively) were consistent with the actual cost estimates of
treating annually obtained for Wenchi (USD 0.40 per person per
year). This supports the estimated 50–60% increase in costs when
treating biannually compared to treating annually. The difficulties
associated with comparing fairly costs among districts within
Ghana exemplify a more general conundrum of comparing results
of health economic analyses conducted in different locations, such
as the complexity of comparing data collected from different
countries with differently structured economies and healthcare
systems, and where public health interventions may comprise
different (e.g. school-based versus community-based) modalities of
delivery.
Our estimated economic cost of CDTI in the Kpandai district,
where both annual and biannual treatments are delivered, likely
reflects more closely the cost of annual rather than biannual CDTI
since only 15 of 76 (20%) of the communities in the sampled sub-
district receive biannual treatment (with the remaining 80%
receiving annual CDTI). This possibly explains why the estimated
cost per person per year in the Kpandai district was only
marginally higher than that in Wenchi (USD 0.43 for the former
versus USD 0.40 for the latter), in which only annual treatments
are delivered. Furthermore, Kpandai has a very high population
density which could reduce the cost per treatment (as found in
[26]). Across the whole district, 122 of 222 (55%) of the
communities are treated annually and the remaining 45% receive
biannual CDTI. Therefore, it is reasonable to expect overall, the
actual cost of ivermectin treatment for Kpandai will lie in between
the estimated costs of annual and biannual CDTI.
Costs Disaggregated by Resource Type and
Programmatic Activity
The costs disaggregated by resource type were consistent among
the sampled districts. These data are also similar to those
presented by McFarland et al. [17]. The recurrent transportation
cost was notably higher in Kpandai compared with the other
districts. This may in part be due to the poorer quality of roads in
the area, resulting in higher vehicle maintenance and fuel costs
(although many other factors, including the spread of the
communities, also affect transportation costs). The costs disaggre-
gated by programmatic activity showed slightly more variation
among districts than among the different resource types. It is
noteworthy that in the Pru and Kintampo North districts (and to a
lesser extent in the Kpandai district), the percentage of the
economic cost attributed to reporting activities at the district, sub-
district, and community levels is substantially higher than that in
the Wenchi district (15% in Pru and Kintampo North compared
to 6% in Wenchi) (Figure 4). This was attributed to the increase in
treatment frequency and is discussed in further detail in the section
on Reported Obstacles Associated with Switching from Annual to Biannual
CDTI.
Community Distributors
The compensation system for CDDs has recently been
implemented in Ghana to cover their transport costs, to facilitate
attendance of training days, and to help serve as an added
incentive. The amount received by CDDs per treatment round
was corroborated at the district health centres. Generally, the
reported amount received by the community distributors was very
consistent across communities and districts.
Accounting for the volunteer CDDs’ time added approximately
USD 0.05 per person per treatment round. The is consistent with
the value reported by Onwujekwe et al. [25], who found that taking
into account volunteer CDD time in two Nigerian communities
added approximately USD 0.07 (2011 prices) per person per
treatment round (using the Nigerian minimum wage to value the
volunteer CDDs’ time). However, both our and the Onwujekwe et
al. [25] estimates are substantially lower than that reported by
McFarland et al. [17], who estimated that accounting for volunteer
CDDs’ time added an average of USD 0.19 (2011 prices) per
treatment round (valuing volunteer time based on the average per
capita Gross National Income (GNI) for each of the three
countries studied in [17], namely, Cameroon, Nigeria and
Uganda). However, this estimate was highly variable between
the different study sites (USD 0.05–0.54 (2011 prices) per
treatment round). The use of different methods to value donated
CDDs’ time (see below) could partly explain the difference (i.e.
estimation using the country’s minimum wage, or using the
country’s per capita GNI). Other possible explanations include the
occurrence of cultural differences affecting the time it takes to
distribute the drug.
As mentioned above, the method used to value the volunteer
CDD’s time has marked effects on the cost output. For example,
we assumed the market value of the volunteer CDD’s time to be
USD 2.36 per day (the minimum wage in Ghana of GHC 3.73
divided by the 1.58 exchange rate [23]) based on the wage that a
farmland worker would receive (i.e. the wage received for the most
common alternative occupation) [21,30]). However, had we
valued the volunteer CDDs’ time using the per capita GNI
method (as used by McFarland et al. [17]), this figure would have
increased to USD 4.96 per day [21,30]. This difference may seem
Table 3. Hypothetical cost (USD) of annual CDTI in Kintampo North and Pru districts, Brong-Ahafo region, Ghana.
Cost Type Estimated Annual Cost Per Person Treated if Annual Distribution were Implemented
Kintampo North Pru
Financial cost 0.42 0.38
Economic cost (excluding volunteer CDD’s time) 0.43 0.39
Economic Cost (including volunteer CDD’s time) 0.47 0.44
Abbreviations and cost explanations as in Table 2.
doi:10.1371/journal.pntd.0002452.t003
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relatively small but when these costs are factored up to the district
level, they can become substantial.
Reported Obstacles Associated with Switching from
Annual to Biannual CDTI
Disease control officers at the district health centres reported
that increasing the treatment frequency to twice per year increased
substantially the amount of time they spent on reporting activities.
This is consistent with the costs disaggregated by programmatic
activity (Figure 4), which indicate that the time spent on reporting
activities increased more than any other project activity when
comparing biannual and annual treatments. This may potentially
lead to delays in ivermectin being delivered to the districts, if the
necessary reports for the next dispatch of drugs are not completed
on time (delivery of the next batch of ivermectin being contingent
on reporting). Delays in the delivery of treatment to communities
not only will have administrative implications, but more impor-
tantly, transmission implications. Treating individuals every 6
months is highly important for transmission suppression, as it has
been estimated that adult O. volvulus female worms start recovering
from the temporary sterilising effects of ivermectin approximately
between three and four months after treatment, and by six months
microfilarial production has recuperated to a substantial degree
[31]. Therefore, delays in treatment will permit more transmission,
ultimately making the disease harder to eliminate and diminishing
the benefit of treating biannually. National onchocerciasis control
programmes which consider increasing CDTI frequency may
need to support reporting activities at the district level and
potentially at the drug donation programme level to encourage
timely reporting but also to allow greater flexibility in deadlines to
minimize delays in drug distribution.
Data Limitations
In Ghana, onchocerciasis control is under the remit of the
NTDP and therefore different disease control programmes are
often integrated. For example, onchocerciasis and lymphatic
filariasis control activities are often carried out simultaneously.
Potentially, this can lead to difficulties in obtaining accurate costs
for a single disease intervention. In addition, this study was
retrospective, and therefore, to a certain extent, the data obtained
were subject to some degree of recall bias.
In order to reduce the time and logistical complexity involved in
collecting the cost data, our sampling strategy was not random, as
we purposely visited local government offices and communities in
districts where CDTI was annual, biannual, or a combination of
the two. However, we were only able to obtain data in one district
that implements annual treatment and one sub-district in each of
the districts. Also, the selected districts may have been more
accessible by road from Accra, the capital of Ghana, than other
more remote locations. Nonetheless, there is no reason to assume
that the costs reported for the sites included in this study (either
delivering annual or biannual CDTI) are not representative of
other sub-districts in the area, nor is there a treatment cost-
associated reason as to why an area switched from annual to
biannual CDTI other than the parasitological criteria listed above.
This is confirmed by the similarity of cost estimation of annual
treatment between the districts delivering only annual CDTI and
the sub-districts also delivering yearly treatment within districts
implementing both strategies. Due to logistic reasons, the regional
level costs in the Northern region were assumed to be the same as
those estimated from Brong-Ahafo region. However, due to
differences between the regions (such as road networks and
community scattering), the costs incurred in the Northern region
may be higher. Nevertheless, this assumption will not affect the
main conclusions of the study regarding the relative costs of annual
vs. biannual treatment.
Concluding Remarks
Our estimate of the cost of annual CDTI is consistent with the
range of values previously reported in the literature [17,25,26].
Our results indicate that the cost of biannual ivermectin treatment
was approximately 50–60% higher than the cost of annual
treatment, and that simply doubling the cost of annual CDTI does
not yield a correct estimate as some studies have assumed [11].
This is higher than estimates for increasing treatment frequency
obtained at smaller scales and when targeting specific age groups,
such as those associated with school-based anthelmintic treatment
programmes [29], which are not truly relevant for onchocerciasis,
but similar to estimates for the more comparable lymphatic
filariasis control programme [28]. Our study will be beneficial in
informing economic evaluations regarding cost-effectiveness anal-
yses of increasing CDTI frequency from annual to biannual in the
African context for the control and elimination of human
onchocerciasis.
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